Bromocriptine Treatment of Prolactin-Secreting Pituitary Adenomas May Restore Pituitary Function
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Six men with prolactin-secreting pituitary macroadenomas and deficiencies of pituitary hormones other than gonadotrophins were treated with bromocriptine for 6 months. During treatment the serum prolactin concentration decreased markedly in all six patients, and in four adenoma size decreased and visual function improved. Two patients who were hypothyroid before bromocriptine treatment were euthyroid during the sixth month of treatment, and the one patient who was hypoadrenal before treatment was euadrenal during treatment. Two of the six men who had subnormal growth hormone secretion before treatment had normal growth hormone secretion during treatment. We conclude that pituitary hormonal functions may improve during bromocriptine treatment for prolactin-secreting pituitary macroadenomas. This improvement may result from decompression of other pituitary cells, because correction of hypothyroidism by bromocriptine was accompanied by conversion from an absent to a normal thyrotrophin response to thyrotrophin-releasing hormone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In these patients, immediate (72 hours) postoperative GH levels, as well as the bilaterality of intrasellar tumor involvement, are significant determinants of subsequent GHD (seen in about 10% of patients) (229).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [229]
Citations
Cites
Galactorrhea: A Study of 235 Cases, Including 48 with Pituitary Tumors
Kleinberg, D. L., Noel, G. L., & Frantz, A. G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703172961103 · Cited by 560
Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine
Thorner, M. O., McNeilly, A. S., Hagan, C., & Besser, G. M. (1974) · BMJ · doi:10.1136/bmj.2.5916.419 · Cited by 406
Response to Thyrotropin Releasing Hormone (TRH) in Normal Man
SNYDER, P. J., & UTIGER, R. D. (1972) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-34-2-380 · Cited by 386
Self-citationRapid Regression of Pituitary Prolactinomas during Bromocriptine Treatment*
THORNER, M. O., MARTIN, W. H., ROGOL, A. D., MORRIS, J. L., PERRYMAN, R. L., CONWAY, B. P., HOWARDS, S. S., WOLFMAN, M. G., & MACLEOD, R. M. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-438 · Cited by 253
Drugs Five Years Later: Bromocriptine
VANCE, M. L., EVANS, W. S., & THORNER, M. O. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-78 · Cited by 242
THE INHIBITION OF PROLACTIN SECRETION IN MAN BY CB-154 (2-Br-α-ergocryptine)
Pozo, E. D., Re, R. B. D., Varga, L., & Friesen, H. (1972) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-35-5-768 · Cited by 201
Variability of hormonal responses to a series of neuroendocrine challenges in depressed patients
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.1.39 · Cited by 170
Self-citationWASS, J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90120-x · Cited by 166
Effects of bromocriptine on pituitary tumour size.
McGregor, A. M., Scanlon, M. F., Hall, R., & Hall, K. (1979) · BMJ · doi:10.1136/bmj.2.6192.700 · Cited by 163
Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*
CHIODINI, P., LIUZZI, A., COZZI, R., VERDEXS, G., OPPIZZI, G., DALLABONZANA, D., SPELTA, B., SILVESTRINI, F., BORGHI, G., LUCCARELLI, G., et al. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-4-737 · Cited by 142
Research works printed but not linked: 1
- 10.1001/jama.1982.03320280031025 · DOI
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas
ARAFAH, B. M. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-6-1173 · Cited by 293
Schlechte, J. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp025334 · Cited by 258
Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas
Webb, S. M., Rigla, M., Wägner, A., Oliver, B., & Bartumeus, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6019 · Cited by 217
DISORDERS OF PROLACTIN SECRETION
Molitch, M. E. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70203-6 · Cited by 182
Metadata
- Authors
- WARFIELD, A., FINKEL, D. M., SCHATZ, N. J., SAVINO, P. J., & SNYDER, P. J.
- Affiliations
- Philadelphia, Pennsylvania
- Corresponding author
- WARFIELD, ANNA
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1984-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 783-785
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2057594155
- Semantic Scholar
- ec85e0f35f25ea7d51003d12c2a207e1bcccf2e5
- Cited by
- 47
- References
- 19
- Citations by year
- 2024: 1 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2013: 1 · 2012: 1
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- bromocriptine, prolactinoma, prolactin-secreting pituitary adenoma, macroadenoma, pituitary function, hypothyroidism, adrenal insufficiency, growth hormone deficiency, thyrotropin-releasing hormone, visual function
- MeSH terms
- Adenoma, Adult, Bromocriptine, Cortodoxone, Humans, Luteinizing Hormone, Male, Middle Aged, Pituitary Neoplasms, Prolactin, Growth Hormone, Testosterone, Thyrotropin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bromocriptine Treatment of Prolactin-Secreting Pituitary Adenomas May Restore Pituitary Function. https://app.cochat.ai/papers/10.7326/0003-4819-101-6-783
- The paper
- WARFIELD, A., FINKEL, D. M., SCHATZ, N. J., SAVINO, P. J., & SNYDER, P. J. (1984). Bromocriptine Treatment of Prolactin-Secreting Pituitary Adenomas May Restore Pituitary Function. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-101-6-783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.